Unlike traditional anti-aging drugs that focus on oxidative stress or telomere length, FOXO4-DRI targets cellular senescence at its root cause, offering a fundamentally new approach to longevity and age-related disease prevention
It is also prescribed for adults with moderate to severe obstructive sleep apnea (OSA) linked to obesity
adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004
Youre comfortable with potentially slightly higher side effect rates for better results
In a double blinded placebo controlled phase 2 study, patients with T2DM and obesity were given intravenous bimagrumab (once every 4 weeks, to a maximum dosage of 1200mg ) in combination with diet and exercise counselling
After discontinuing treatment due to the temporary unavailability of the drug, she regained 7 kg in three months, increasing her body weight to 120 kg (body mass index 59.9 kg/m2)